Company intelligence / Profile preview

Pluri Consult

Haifa, Haifa, Israelpluriconsultblog.wordpress.com ↗

Ownership: Private
Development stage: Other

Overview

Pluri’s lead product candidate "Emiplacel" is in Phase 3 trials for muscle injury. "Avoplacel" is in Phase 2 trials for acute radiation syndrome. The company also has a discovery-stage MAIT cell immunotherapy program targeting solid tumors. Clinical results to date have demonstrated safety and potential efficacy in target indications; however, no products are yet approved or commercialized as of June 2025

Therapeutic areas: OtherOncologyHematology
Modalities: Cell therapyMesenchymal stem cell therapyStem cell therapy
Industry: Biotech

Partnerships

Tnuva Food Industries (cultivated meat collaboration)Tnuva Food-Tech Incubator (cultivated meat collaboration)Bar-Ilan University (cancer immunotherapy research partnership)

Beyond the preview

Go deeper on Pluri Consult.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluri Consult.

Explore the full profile